Limited knowledge on progestogen-only contraception and risk of venous thromboembolism

Acta Obstetricia et Gynecologica Scandinavica

Volumn 88, Issue 3, 2009, Pages 261-266

  Bergendal, Annica ^a,b   Odlind, Viveca ^c,d   Persson, Ingemar ^a,c   Kieler, Helle ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c MEDICAL PRODUCTS AGENCY   (Sweden)

^d UPPSALA UNIVERSITY   (Sweden)

Author keywords

Epidemiology; Observational studies; Progestogen only contraception; Systematic review; Venous thromboembolism

Indexed keywords

CHLORMADINONE; GESTAGEN; ORAL CONTRACEPTIVE AGENT;

ACUTE HEART INFARCTION; CASE CONTROL STUDY; HUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SYSTEMATIC REVIEW; VENOUS THROMBOEMBOLISM;

CASE-CONTROL STUDIES; COHORT STUDIES; CONTRACEPTIVES, ORAL, HORMONAL; FEMALE; HUMANS; ODDS RATIO; PROGESTINS; RISK ASSESSMENT; VENOUS THROMBOEMBOLISM;

EID: 60849108646     PISSN: 00016349     EISSN: 16000412     Source Type: Journal    
DOI: 10.1080/00016340902730375     Document Type: Review

References (24)

1. Winkler UH. Blood coagulation and oral contraceptives. A critical review. Contraception. 1998;57:203-9.
2. Winkler UH, Holscher T, Schulte H, Zierleyn JP, Collet W, Schindler AE. Ethinylestradiol 20 versus 30 micrograms combined with 150 micrograms desogestrel: a large comparative study of the effects of two low-dose oral contraceptives on the hemostatic system. Gynecol Endocrinol. 1996;10:265-71.
3. Mammen EF. Pathogenesis of venous thrombosis. Chest. 1992;102:640S-4.
4. Kuhl H. Effects of progestogens on haemostasis. Maturitas. 1996;24:1-19.
5. van Rooijen M, Silveira A, Thomassen S, Hansson LO, Rosing J, Hamsten A, et al. Rapid activation of haemostasis after hormonal emergency contraception. Thromb Haemost. 2007;97:15-20.
6. Schindler AE. Differential effects of progestins on hemostasis. Maturitas. 2003;46:S31-7.
7. Bax L, Yu LM, Ikeda N, Tsuruta H, Moons KG. Development and validation of MIX: comprehensive free software for meta-analysis of causal research data. BMC Med Res Methodol. 2006;6:50.
8. Lewis MA, Heinemann LA, MacRae KD, Bruppacher R, Spitzer WO. The increased risk of venous thromboembolism and the use of third generation progestagens: role of bias in observational research. The Transnational Research Group on Oral Contraceptives and the Health of Young Women. Contraception. 1996;54:5-13.
9. World Health Organization CSoCDaSHC. Cardiovascular disease and use of oral and injectable progestogen-only contraceptives and combined injectable contraceptives. Results of an international, multicenter, case-control study. Contraception. 1998;57:315-24.
10. Heinemann LA, Assmann A, DoMinh T, Garbe E. Oral progestogen-only contraceptives and cardiovascular risk: results from the Transnational Study on Oral Contraceptives and the Health of Young Women. Eur J Contracept Reprod Health Care. 1999;4:67-73.
11. Vasilakis C, Jick H, del Mar Melero-Montes M. Risk of idiopathic venous thromboembolism in users of progestagens alone. Lancet. 1999;354:1610-1.
12. Lidegaard O, Edstrom B, Kreiner S. Oral contraceptives and venous thromboembolism: a five-year national case-control study. Contraception. 2002;65:187-96.
13. Conard J, Plu-Bureau G, Bahi N, Horellou MH, Pelissier C, Thalabard JC. Progestogen-only contraception in women at high risk of venous thromboembolism. Contraception. 2004;70:437-41.
14. Zheng SR, Zheng HM, Qian SZ, Sang GW, Kaper RF. A randomized multicenter study comparing the efficacy and bleeding pattern of a single-rod (Implanon) and a six-capsule (Norplant) hormonal contraceptive implant. Contraception. 1999;60:1-8.
15. Hirani V, Zaninotto P, Primatesta P. Generalised and abdominal obesity and risk of diabetes, hypertension and hypertension-diabetes co-morbidity in England. Public Health Nutr. 2008;11:521-7.
16. Doyle J, Stern L, Hagan M, Hao J, Gricar J. Advances in contraception: IUDs from a managed care perspective. J Womens Health (Larchmt). 2008;17:987-92.
17. Vandenbroucke JP, Rosing J, Bloemenkamp KW, Middeldorp S, Helmerhorst FM, Bouma BN, et al. Oral contraceptives and the risk of venous thrombosis. N Engl J Med. 2001;344:1527-35.
18. Herkert O, Kuhl H, Sandow J, Busse R, Schini-Kerth VB. Sex steroids used in hormonal treatment increase vascular procoagulant activity by inducing thrombin receptor (PAR-1) expression: role of the glucocorticoid receptor. Circulation. 2001;104:2826-31.
19. Miller J, Chan BK, Nelson HD. Postmenopausal estrogen replacement and risk for venous thromboembolism: a systematic review and meta-analysis for the U.S. Preventive Services Task Force. Ann Intern Med. 2002;136:680-90.
20. Whigham KA, Howie PW, Mack A, Prentice CR. The effect of an injectable progestogen contraceptive on blood coagulation and fibrinolysis. Br J Obstet Gynaecol. 1979;86:806-9.
21. Blomback M, Landgren BM, Stiernholm Y, Andersson O. The effect of progesterone on the haemostatic mechanism. Thromb Haemost. 1997;77:105-8.
22. Singh K, Viegas OA, Koh SC, Ratnam SS. Effect of long-term use of Norplant implants on haemostatic function. Contraception. 1992;45:203-19.
23. Lira P, Rivera L, Diaz S, Croxatto HB. Study of blood coagulation in women treated with megestrol acetate implants. Contraception. 1975;12:639-44.
24. World Health Organization CSoCDaSHC. Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study. Lancet. 1995;346:1575-82.